Wolfe Research has initiated coverage on Soleno Therapeutics Inc (SLNO) with an Outperform rating, marking the firm's first assessment of the company's investment potential. This decision reflects an analysis of Soleno's business dynamics and growth prospects within the biotechnology sector.
Headquartered in Redwood City, California, Soleno Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases. The company's lead product candidate, diazoxide choline extended-release tablets (DCCR), targets Prader-Willi syndrome in individuals four years and older who experience hyperphagia. DCCR has received Breakthrough Therapy and Fast-Track designations in the United States, as well as Orphan Drug designations in both the United States and the European Union.
Currently, Soleno Therapeutics has a market capitalization of $2.6 billion and an earnings per share (EPS) of -1.84. The company is set to report its upcoming earnings on May 4, 2026, with an estimated EPS of $0.62 and revenue expectations of $88.7 million.
Analyst ratings can provide insights, but they are based on assumptions that may not always hold true. Investors are encouraged to consider a range of factors, including company fundamentals and market trends, when making decisions. Analyst ratings can change over time as new information emerges, and different firms may have varying views on the same stock.